Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literature Review
-
Published:2023-03-27
Issue:4
Volume:11
Page:1024
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Hertelendi Marianna1, Belguenani Oulaya1, Cherfi Azzeddine2, Folitar Ilya2ORCID, Kollar Gabor1, Polack Berna Degirmenci3
Affiliation:
1. Advanced Accelerator Applications International SA, 4 Rue de la Tour de l’Ile, 1204 Geneva, Switzerland 2. Novartis Pharma AG, 4002 Basel, Switzerland 3. Novartis Pharmaceuticals, One Health Plaza, East Hanover, NJ 07936-1080, USA
Abstract
Background: We have performed a systematic review to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE, a radioligand therapy, in advanced somatostatin receptor-positive pheochromocytoma/paraganglioma (PPGL), thymic neuroendocrine tumor (NET), bronchial NET, unknown primary NET, or medullary thyroid carcinoma (MTC). Methods: Studies identified in PubMed from inception to 13 May 2021 must have assessed [177Lu]Lu-DOTA-TATE as a single agent and reported outcome data for the specific NET types of interest. Results: Two independent reviewers performed the screening and data extraction, resulting in 16 publications: PPGL (n = 7), bronchial NETs (n = 6; one also included NETs of unknown origin), and MTC (n = 3). Overall, [177Lu]Lu-DOTA-TATE offers encouraging antitumor activity (overall tumor response rates and disease control rates) across NET types. Safety was favorable with most adverse events mild to moderate in severity, transient, and consistent with those seen in patients with gastroenteropancreatic (GEP)-NETs. Conclusions: [177Lu]Lu-DOTA-TATE has been used effectively in clinical practice to treat NETs of non-GEP origin.
Funder
Advanced Accelerator Applications, a Novartis company
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference52 articles.
1. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms;Hofland;Endocr. Rev.,2020 2. A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal;Rindi;Mod. Pathol.,2018 3. Stueven, A.K., Kayser, A., Wetz, C., Amthauer, H., Wree, A., Tacke, F., Wiedenmann, B., Roderburg, C., and Jann, H. (2019). Somatostatin analogues in the treatment of neuroendocrine tumors: Past, present and future. Int. J. Mol. Sci., 20. 4. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States;Dasari;JAMA Oncol.,2017 5. Advanced Accelerator Applications USA, Inc. (2022, January 05). LUTATHERA® US Prescribing Information. Available online: https://www.novartis.us/sites/www.novartis.us/files/lutathera.pdf.
|
|